The DOI matches its Crossref record; 72 of the 72 references it cites were found in a registry or an index.
HDAC inhibitors: Clinical update and mechanism-based potential
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The language of covalent histone modifications
Strahl, B. D., & Allis, C. D. (2000) · Nature · doi:10.1038/47412 · Cited by 8,679
5-Fluorouracil: mechanisms of action and clinical strategies
Longley, D. B., Harkin, D. P., & Johnston, P. G. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1074 · Cited by 5,332
Anticancer activities of histone deacetylase inhibitors
Bolden, J. E., Peart, M. J., & Johnstone, R. W. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2133 · Cited by 2,919
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer
Minucci, S., & Pelicci, P. G. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1779 · Cited by 2,200
A Mammalian Histone Deacetylase Related to the Yeast Transcriptional Regulator Rpd3p
Taunton, J., Hassig, C. A., & Schreiber, S. L. (1996) · Science · doi:10.1126/science.272.5260.408 · Cited by 1,829
Histone acetylation and an epigenetic code
Turner, B. M. (2000) · BioEssays · doi:10.1002/1521-1878(200009)22:9<836::aid-bies9>3.0.co;2-x · Cited by 1,182
Duvic, M., Talpur, R., Ni, X., Zhang, C., Hazarika, P., Kelly, C., Chiao, J. H., Reilly, J. F., Ricker, J. L., Richon, V. M., et al. (2007) · Blood · doi:10.1182/blood-2006-06-025999 · Cited by 1,141
Haggarty, S. J., Koeller, K. M., Wong, J. C., Grozinger, C. M., & Schreiber, S. L. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0430973100 · Cited by 1,066
(2002) · PubMed · Cited by 732
Dynamic Regulation of Histone Lysine Methylation by Demethylases
Shi, Y., & Whetstine, J. R. (2007) · Molecular Cell · doi:10.1016/j.molcel.2006.12.010 · Cited by 707
Repression of p53 activity by Smyd2-mediated methylation
Huang, J., Perez-Burgos, L., Placek, B. J., Sengupta, R., Richter, M., Dorsey, J. A., Kubicek, S., Opravil, S., Jenuwein, T., & Berger, S. L. (2006) · Nature · doi:10.1038/nature05287 · Cited by 624
(2003) · PubMed · Cited by 519
Depletion of latent HIV-1 infection in vivo: a proof-of-concept study
Lehrman, G., Hogue, I. B., Palmer, S., Jennings, C., Spina, C. A., Wiegand, A., Landay, A. L., Coombs, R. W., Richman, D. D., Mellors, J. W., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67098-5 · Cited by 510
Sandor, V. A., Bakke, S., Robey, R. W., Kang, M. H., Blagosklonny, M. V., Bender, J., Brooks, R. A., Piekarz, R., Tucker, E. E., Figg, W. D., et al. (2002) · PubMed · Cited by 502
Warrell, R. P., He, L.-Z., Richon, V., Calleja, E., & Pandolfi, P. P. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.21.1621 · Cited by 502
CLINICAL DEVELOPMENT OF HISTONE DEACETYLASE INHIBITORS AS ANTICANCER AGENTS
Drummond, D. C., Noble, C. O., Kirpotin, D. B., Guo, Z., Scott, G. K., & Benz, C. C. (2005) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.45.120403.095825 · Cited by 494
FR901228, a Potent Antitumor Antibiotic, Is a Novel Histone Deacetylase Inhibitor
Nakajima, H., Kim, Y. B., Terano, H., Yoshida, M., & Horinouchi, S. (1998) · Experimental Cell Research · doi:10.1006/excr.1998.4027 · Cited by 487
(2003) · PubMed · Cited by 465
Piekarz, R. L., Robey, R., Sandor, V., Bakke, S., Wilson, W. H., Dahmoush, L., Kingma, D. M., Turner, M. L., Altemus, R., & Bates, S. E. (2001) · Blood · doi:10.1182/blood.v98.9.2865 · Cited by 445
Ng (2000) · doi:10.1016/s0968-0004(00)01551-6 · Cited by 427
Genomewide studies of histone deacetylase function in yeast
Bernstein, B. E., Tong, J. K., & Schreiber, S. L. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.250477697 · Cited by 421
Furumai, R., Komatsu, Y., Nishino, N., Khochbin, S., Yoshida, M., & Horinouchi, S. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.98.1.87 · Cited by 412
Ryan, Q. C., Headlee, D., Acharya, M., Sparreboom, A., Trepel, J. B., Ye, J., Figg, W. D., Hwang, K., Chung, E. J., Murgo, A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.188 · Cited by 411
O'Connor, O. A., Heaney, M. L., Schwartz, L., Richardson, S., Willim, R., MacGregor-Cortelli, B., Curly, T., Moskowitz, C., Portlock, C., Horwitz, S., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.9679 · Cited by 404
Turner, B. M. (2007) · Nature Cell Biology · doi:10.1038/ncb0107-2 · Cited by 391
Modulation of p53, ErbB1, ErbB2, and Raf-1 Expression in Lung Cancer Cells by Depsipeptide FR901228
Yu, X. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.7.504 · Cited by 360
Plumb, J. A., Finn, P. W., Williams, R. J., Bandara, M. J., Romero, M., Watkins, C. J., Thangue, N. B. L., & Brown, R. E. (2003) · PubMed · Cited by 312
Epigenetics provides a new generation of oncogenes and tumour-suppressor genes
Esteller, M. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6602918 · Cited by 284
Gojo, I., Jiemjit, A., Trepel, J. B., Sparreboom, A., Figg, W. D., Rollins, S., Tidwell, M. L., Greer, J., Chung, E. J., Lee, M.-J., et al. (2007) · Blood · doi:10.1182/blood-2006-05-021873 · Cited by 281
Nimmanapalli, R., Fuino, L., Bali, P., Gasparetto, M., Glozak, M. A., Tao, J., Moscinski, L. C., Smith, C. A., Wu, J., Jove, R., et al. (2003) · PubMed · Cited by 276
Reading signals on the nucleosome with a new nomenclature for modified histones
Turner, B. M. (2005) · Nature Structural & Molecular Biology · doi:10.1038/nsmb0205-110 · Cited by 258
Faraco, G., Pancani, T., Formentini, L., Mascagni, P., Fossati, G., Leoni, F., Moroni, F., & Chiarugi, A. (2006) · Molecular Pharmacology · doi:10.1124/mol.106.027912 · Cited by 255
Ylisastigui, L., Archin, N. M., Lehrman, G., Bosch, R. J., & Margolis, D. M. (2004) · AIDS · doi:10.1097/00002030-200405210-00003 · Cited by 254
Zhang, C., Richon, V., Ni, X., Talpur, R., & Duvic, M. (2005) · Journal of Investigative Dermatology · doi:10.1111/j.0022-202x.2005.23925.x · Cited by 242
Piekarz, R. L., Frye, A. R., Wright, J. J., Steinberg, S. M., Liewehr, D. J., Rosing, D. R., Sachdev, V., Fojo, T., & Bates, S. E. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2095 · Cited by 232
Yang, X., Ferguson, A. T., Nass, S. J., Phillips, D. L., Butash, K. A., Wang, S. M., Herman, J. G., & Davidson, N. E. (2000) · PubMed · Cited by 228
Brogdon, J. L., Xu, Y., Szabo, S. J., An, S., Buxton, F., Cohen, D., & Huang, Q. (2007) · Blood · doi:10.1182/blood-2006-04-019711 · Cited by 227
Munshi, A., Tanaka, T., Hobbs, M. L., Tucker, S. L., Richon, V. M., & Meyn, R. E. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0022 · Cited by 219
Role of Class I and Class II histone deacetylases in carcinoma cells using siRNA
Glaser, K. B., Li, J., Staver, M. J., Wei, R.-Q., Albert, D. H., & Davidsen, S. K. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2003.09.043 · Cited by 218
Self-citationHistone deacetylase inhibitors as therapeutics for polyglutamine disorders
Butler, R., & Bates, G. P. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1989 · Cited by 214
Sharma, D., Saxena, N. K., Davidson, N. E., & Vertino, P. M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0402 · Cited by 208
Su, G. H., Sohn, T. A., Ryu, B., & Kern, S. E. (2000) · PubMed · Cited by 189
Piekarz, R. L., Robey, R. W., Zhan, Z., Kayastha, G., Sayah, A., Abdeldaim, A. H., Torrico, S., & Bates, S. E. (2004) · Blood · doi:10.1182/blood-2003-09-3068 · Cited by 186
Histone deacetylase 4 interacts with 53BP1 to mediate the DNA damage response
Kao, G. D., McKenna, W. G., Guenther, M. G., Muschel, R. J., Lazar, M. A., & Yen, T. J. (2003) · The Journal of Cell Biology · doi:10.1083/jcb.200209065 · Cited by 179
Zhou, Q., Atadja, P., & Davidson, N. E. (2007) · Cancer Biology & Therapy · doi:10.4161/cbt.6.1.3549 · Cited by 160
Reid, G., Métivier, R., Lin, C., Denger, S., Ibberson, D., Ivacevic, T., Brand, H., Beneš, V., Liu, E. T., & Gannon, F. (2005) · Oncogene · doi:10.1038/sj.onc.1208662 · Cited by 154
Keen, J. C., Lan, Y., Mack, K. M., Pettit, C., Smith, D., Sharma, D., & Davidson, N. E. (2003) · Breast Cancer Research and Treatment · doi:10.1023/a:1026146524737 · Cited by 151
Fiskus, W. C., Pranpat, M., Bali, P., Balasis, M. E., Kumaraswamy, S., Boyapalle, S., Rocha, K., Wu, J., Giles, F. J., Manley, P. W., et al. (2006) · Blood · doi:10.1182/blood-2005-11-4639 · Cited by 145
Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies
Qian, X., LaRochelle, W. J., Ara, G., Wu, F. S.-Y., Petersen, K. D., Thougaard, A., Sehested, M., Lichenstein, H. S., & Jeffers, M. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0111 · Cited by 139
Histone deacetylase inhibitors: insights into mechanisms of lethality
Rosato, R. R., & Grant, S. (2005) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.9.4.809 · Cited by 139
Bali, P., George, P., Cohen, P. S., Tao, J., Guo, F., Sigua, C. A., Vishvanath, A., Scuto, A., Annavarapu, S., Fiskus, W. C., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0210 · Cited by 128
Zhou, D.-C., Kim, S. H., Ding, W., Schultz, C. L., Warrell, R. P., & Gallagher, R. E. (2002) · Blood · doi:10.1182/blood.v99.4.1356 · Cited by 118
Tabe, Y., Konopleva, M. Y., Contractor, R., Munsell, M. F., Schober, W. D., Jin, L., Tsutsumi‐Ishii, Y., Nagaoka, I., Igari, J., & Andreeff, M. (2005) · Blood · doi:10.1182/blood-2004-10-4126 · Cited by 106
Inoue, K., Kobayashi, M., Yano, K., Miura, M., Izumi, A., Mataki, C., Doi, T., Hamakubo, T., Reid, P., Hume, D. A., et al. (2006) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000247247.89787.e7 · Cited by 105
Lee, J., Park, J., Jung, Y., Kim, J.-H., Jong, H.-S., Kim, T., & Bang, Y. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0419 · Cited by 103
Fiskus, W. C., Pranpat, M., Balasis, M. E., Bali, P., Estrella, V. C., Kumaraswamy, S., Rao, R., Rocha, K., Herger, B. E., Lee, F. Y., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0980 · Cited by 102
Histone deacetylase inhibitors in clinical development
Rosato, R. R., & Grant, S. (2004) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.13.1.21 · Cited by 101
Spiruchostatins A and B, novel gene expression-enhancing substances produced by Pseudomonas sp.
Masuoka, Y., Nagai, A., Shin‐ya, K., Furihata, K., Nagai, K., Suzuki, K., Hayakawa, Y., & Seto, H. (2001) · Tetrahedron Letters · doi:10.1016/s0040-4039(00)01874-8 · Cited by 100
Zhang, X., Yashiro, M., Ren, J., & Hirakawa, K. (2006) · Oncology Reports · doi:10.3892/or.16.3.563 · Cited by 81
FK228 (depsipeptide): a HDAC inhibitor with pleiotropic antitumor activities
Konstantinopoulos, P. A., Vandoros, G. P., & Papavassiliou, A. G. (2006) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-005-0182-5 · Cited by 78
Histone Deacetylase Inhibitors: The Abbott Experience
Curtin, M. L., & Glaser, K. B. (2003) · Current Medicinal Chemistry · doi:10.2174/0929867033456576 · Cited by 78
Self-citationTumber, A., Collins, L. S., Petersen, K. D., Thougaard, A., Christiansen, S., Dejligbjerg, M., Jensen, P. B., Sehested, M., & Ritchie, J. W. A. (2006) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-006-0374-7 · Cited by 77
Sadri‐Vakili, G., & Cha, J.-H. J. (2006) · Current Alzheimer Research · doi:10.2174/156720506778249407 · Cited by 71
Ocker, M., Alajati, A., Ganslmayer, M., Zopf, S., L�ders, M., Neureiter, D., Hahn, E. G., Schuppan, D., & Herold, C. (2005) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-004-0664-6 · Cited by 67
Differential protein acetylation induced by novel histone deacetylase inhibitors
Glaser, K. B., Li, J., Pease, L. J., Staver, M. J., Marcotte, P. A., Guo, J., Frey, R. R., Garland, R. B., Heyman, H. R., Wada, C. K., et al. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.10.082 · Cited by 67
Self-citationExpression and functional characterization of recombinant human HDAC1 and HDAC3
Li, J., Staver, M. J., Curtin, M. L., Holms, J. H., Frey, R. R., Edalji, R. P., Smith, R. A., Michaelides, M. R., Davidsen, S. K., & Glaser, K. B. (2004) · Life Sciences · doi:10.1016/j.lfs.2003.09.070 · Cited by 46
Self-citationMasuoka, Y., Shin‐ya, K., KIM, Y.-B., Yoshida, M., Nagai, K., Suzuki, K., Hayakawa, Y., & Seto, H. (2000) · The Journal of Antibiotics · doi:10.7164/antibiotics.53.788 · Cited by 23
High-Throughput Drug Screening of the DPC4 Tumor-Suppressor Pathway in Human Pancreatic Cancer Cells
Sohn, T. A., Su, G. H., Ryu, B., Yeo, C. J., & Kern, S. E. (2001) · Annals of Surgery · doi:10.1097/00000658-200105000-00014 · Cited by 23
Glaser, K. B., Li, J., Aakre, M. E., Morgan, D. W., Sheppard, G. S., Stewart, K. D., Pollock, J. S., Lee, P., O'Connor, C. Z., Anderson, S. N., et al. (2002) · PubMed · Cited by 22
Self-citationMasuoka, Y., Shin‐ya, K., FURIHATA, K., Hayakawa, Y., & Seto, H. (1997) · The Journal of Antibiotics · doi:10.7164/antibiotics.50.1058 · Cited by 18
Beliën, A., Schepper, S. D., Floren, W., Janssens, B., Mariën, A., King, P., Dun, J. V., Andries, L. J., Voeten, J., Bijnens, L., et al. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0112 · Cited by 9
Grant, S. (2004) · Leukemia · doi:10.1038/sj.leu.2403522 · Cited by 8
Cited by
Therapeutic application of histone deacetylase inhibitors for central nervous system disorders
Kazantsev, A. G., & Thompson, L. M. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2681 · Cited by 711
Natural products as leads to anticancer drugs
Gordaliza, M. (2007) · Clinical and Translational Oncology · doi:10.1007/s12094-007-0138-9 · Cited by 701
Epigenetics in cancer: Targeting chromatin modifications
Ellis, L., Atadja, P. W., & Johnstone, R. W. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0860 · Cited by 479
Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents
Tan, J., Cang, S., Ma, Y., Petrillo, R. L., & Liu, D. (2010) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-3-5 · Cited by 425
Histone deacetylase inhibitors: Mechanisms of cell death and promise in combination cancer therapy
Carew, J. S., Giles, F. J., & Nawrocki, S. T. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.03.037 · Cited by 421
Metadata
- Authors
- Glaser, K. B.
- Venue
- Biochemical Pharmacology
- Publisher
- Elsevier BV
- Published
- 2007-09
- Volume
- 74
- Issue
- 5
- Pages
- 659-671
- ISSN
- 0006-2952 (ISSN-L)
- OpenAlex
- W2009204250
- Cited by
- 348
- References
- 72
- FWCI
- 17.36
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.